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Earlier, the personalised “3S” paradigm of preclinical anti-
cancer drug testing was developed in parallel with a new
conception of predictive, preventive, and personalised
medicine. The paradigm includes three main points: 1) Set
of complementary mouse models to reproduce a wide
range of human breast cancer (BC) types; 2) Steps of pre-
clinical anti-cancer drug testing procedure starting from in
vitro and in vivo research on transplanted and sponta-
neous BC mouse models followed by probing of preven-
tive regimen(s); (3) Stratified sampling as a methodology
to distinguish more homogeneous subgroups within a het-
erogeneous population of experimental inbred mice using
maximal number of individual recipient characteristics
before and after testing procedure. This personalised pro-
cedure permits revealing of both positive and negative
effects of a given drug.
Two types of different mouse models for preventive
regimen testing exist within our paradigm; while com-
monly used preclinical drug testing procedures rarely
include preventive regimen tests as one-level trans-
planted models are generally accepted. In contrast, our
multistage conception proposes both transplanted and
spontaneous BC mouse models using. The key advan-
tage of a transplantable model is simultaneous develop-
ing of several homogenous populations of tumour-
bearing mice. However, this mouse model preserves
well-known limitations as healthy young recipient mice
do not reflect numerous main characteristics of cancer
patients that are mostly aged having a number of conco-
mitant chronic inflammatory diseases. Furthermore,
autochthonous carcinogenesis in humans and mice is a
multi-staged process that is characterised as gradual
transformation of cells and evolutionary expansion of
cell populations in situ; and immune system is supposed
to play a key role in this process. Earlier, we showed
that our non-SPF conventional mouse strains with high
frequency of spontaneous BC in aged females with pre-
ceded inflammatory diseases mimic the human BC
aetiology/morphology properly. Several studies of pre-
ventive regimen tests in both transplanted and pre-
cancerous spontaneous models are presented here to
illustrate the acceptability of our paradigm. Firstly, a
number of prestart transplanted mouse models of BC
were used to test preventive regimens of immunother-
apy by interleukin-2 and Imunofan®. In majority of our
experiments, a single application of immunostimulants 3
days before tumour cell inoculation resulted in signifi-
cant stimulation of tumour appearance in treated male
recipients. In parallel, pre-cancerous BLRB and CBRB
aged females were used as spontaneous models to test
preventive regimens of the same immunostimulants. In
contrast with above-mentioned data, clear age-related
inhibition of BC appearance in pre-cancerous treated
groups was observed. Transplanted mouse models
hardly may be considered as an adequate model to test
preventive regimens of immunotherapy against BC; but
this test is suggested to compare extent of efficacy of
various immunostimulants. While prophylactic anti-can-
cer effect of used drugs was revealed in aged pre-cancer-
ous females, obtained contradictory data warn against
uncontrolled usage of immunostimulants in breast can-
cer prone population. In summary, our original anti-
cancer drug methodology demonstrates practical and
scientific applicability.
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